Vaiomer is focused on the discovery and development of novel biomarkers and targets for type 2 diabetes and its cardiovascular complications. Our work is based on the concept, discovered by R. Burcelin and J. Amar, that tissue microbiota play a causal role in triggering an inflammatory cascade that leads to metabolic disorders.
Unlike currently available tests, notably Fasting Blood Glucose assays, Vaiomer’s biomarkers reflect the cause and not the consequence of the pathology, thus permitting early detection. This represents an important differentiating factor in relation to other biomarkers and provides a considerable commercial advantage.
The new paradigm also permits the identification of new targets for drug discovery and vaccines.
Vaiomer is awarded a Mérieux Research Grant from the Institute Mérieux...
Vaiomer and the French pharmaceutical company Servier announce signature of collaboration agreement.....
Click here to read
Vaiomer is awarded start up trophy in "Etoiles de la santé" awards....
Vaiomer is awarded French national prize for innovation....